Dara BioSciences, Inc. announced a partnership with Seyer Pharmatec, Inc. for the exclusive distribution of Dara’s breast cancer drug Soltamox in Puerto Rico.
In January, the Raleigh-based company bought Oncogenerix, a small South Carolina-based pharmaceutical company. The acquisition gave Dara the American rights to Soltamox, which is a liquid version of the widely used breast cancer drug tamoxifen.
Already sold in the United Kingdom and approved by the FDA for use in the United States, Soltamox is expected to go on sale in the U.S. later this year. The company expects the drug to achieve revenue of up to $20 million in the next five years.
The liquid version of the drug will help patients who are unable to swallow pills due to their cancer treatment.
In addition to Soltamox, Dara is working on drugs to treat cancer and diabetes.